Prescient Therapeutics Share Price and Company Fundamentals
Last traded: Today at 4:59 AM
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
Key Metrics
PE ratio
-
PB ratio
5.29
Dividend yield
-
Beta
0.22
Market cap
$77.81M
Enterprise value
$54.28M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://ptxtherapeutics.com |
| Mailing address | Suite 2 Level 11 385 Bourke Street Melbourne VIC 3000 Australia |
| Phone / Fax | 61 3 9692 7222 / 61 3 9077 9233 |
Dividends
More: Prescient Therapeutics Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Prescient Therapeutics paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.PTX dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Prescient Therapeutics.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. James McDonnell | Chief Executive Officer | ||
| Ms. Melanie Jaye Leydin B.Bus, C.A. | CFO & Company Secretary | 52 | |
| Dr. Rebecca Tunstall | Chief Operating Officer | ||
| Dr. Marissa Lim M.B.A., MBBS | Chief Medical Officer |
Profitability and management effectiveness
Profit margin
-168.09%
Operating margin
-158.43%
Return on assets
-26.95%
Return on equity
-49.72%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Prescient Therapeutics is 77.81M and its enterprise value is 54.28M. The enterprise value to revenue ratio of PTX is 12.46. The enterprise value to EBITDA ratio of PTX is -7.20.
The PTX's stocks Beta value is 0.22 making it 78% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Prescient Therapeutics (PTX)
Prescient Therapeutics (ASX:PTX) Frequently Asked Questions
1. What is Prescient Therapeutics's Stock Symbol?
Prescient Therapeutics trades on ASX under the ticker symbol "PTX".
2. What is Prescient Therapeutics's stock price today?
One share of PTX stock can currently be purchased for approximately $0.074.
3. How can I contact Prescient Therapeutics?
Prescient Therapeutics's mailing address is Suite 2 Level 11 385 Bourke Street Melbourne VIC 3000 Australia. The company can be reached via phone at 61 3 9692 7222.
4. What is Prescient Therapeutics's official website?
The official website of Prescient Therapeutics is https://ptxtherapeutics.com.